Antibodies
Q-VD-OPh
- 貨號 Cat. No.
- S7311
- 規格 Size
- 5~200mg
- 品牌 Brand
- Selleckchem
Description
Q-VD-OPh
Catalog No.S7311
Q-VD-OPh is a potent pan-caspase inhibitor with IC50 ranging from 25 to 400 nM for caspases 1, 3, 8, and 9, showing inhibitory effects on terminal caspase activation, substrate cleavage, and DNA ladder formation associated with apoptosis.
| Availability |
|---|
The item is temporarily out of stock. Please leave your email address and we will inform you when we have it in stock. Just click the Arrival Notice and leave your email address to get 10% off. Arrival Notice |
Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw
Biological Activity
| Description | Q-VD-OPh is a potent pan-caspase inhibitor with IC50 ranging from 25 to 400 nM for caspases 1, 3, 8, and 9, showing inhibitory effects on terminal caspase activation, substrate cleavage, and DNA ladder formation associated with apoptosis. | |||||
|---|---|---|---|---|---|---|
| Targets | Caspases 1, 3, 8, 9 | |||||
| IC50 | 25-400 nM [1] | |||||
| In vitro | Q-VD-OPh （5-100 μM） potently inhibits Actinomycin D-induced DNA laddering and subsequent apoptosis with minimal toxicity in WEHI 231 cells. Q-VD-OPh prevents caspase mediated cleavage of PARP and activation of the major initiator and effector caspases. [2] Q-VD-OPh protects cardiac myocytes from virus-induced apoptosis in vitro. [4] | |||||
| In vivo | Q-VD-OPh inhibits caspase-1 activity, IL-18 protein expression, and neutrophil infiltration during ischemic ARF in mice. [3] In vivo, caspase inhibition by Q-VD-OPh provides protection from virus-induced myocardial injury, with a significant reduction in caspase-3 activity. [4] In TgCRND8 mice, Q-VD-OPh inhibits caspase-7 activation and limits the pathological changes associated with tau, including caspase cleavage. [5] | |||||
| Features | ||||||
Protocol(Only for Reference)
Cell Assay: [2]
| Cell lines | WEHI-231 cells |
|---|---|
| Concentrations | ~1000 μM |
| Incubation Time | 4 hours |
| Method | Caspase inhibitors are added at the indicated concentrations 30 minutes prior to the addition of apoptotic stimuli. Viability and cell number are determined by trypan blue exclusion from three random fields of greater than 200 cells/field. All experiments are performed a minimum of three times. |
Animal Study: [3]
| Animal Models | C57BL/6 mice |
|---|---|
| Dosages | ~120 mg/kg |
| Administration | Intraperitoneal administration |
References
Chemical Information
| Molecular Weight (MW) | 513.49 |
|---|---|
| Formula | C26H25F2N3O6 |
| CAS No. | 1135695-98-5 |
| Storage | 3 years -20℃Powder |
|---|---|
| 6 months-80℃in DMSO | |
| Syonnyms | N/A |
| Solubility (25°C) * | In vitro | DMSO | mg/mL (<1 mM) |
|---|---|---|---|
| Water | mg/mL (<1 mM) | ||
| Ethanol | mg/mL (<1 mM) | ||
| * <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. | |||
| Chemical Name | Pentanoic acid, 5-​(2,​6-​difluorophenoxy)​-​3-​[[(2S)​-​3-​methyl-​1-​oxo-​2-​[(2-​quinolinylcarbonyl)​amino]​butyl]​amino]​-​4-​oxo-​, (3S)​- |
|---|
